LifeMD, Inc.
LFMDHealthcareNASDAQHealth Information Services
Scan Results
Daily timeframePart of the healthcare sector, LifeMD, Inc. (LFMD) is listed under Health Information Services. With a market capitalization of $197.8M, it sits in micro-cap territory. It offers telehealth platform comprising Rex MD, a men's telehealth platform that provides virtual diagnosis, treatment, and prescription medications for men's health conditions, including erectile dysfunction, premature ejaculation, hair loss, insomnia, weight loss, and performance anxiety; and ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss.
Market Cap
$197.8M
Beta
1.99
P/E (TTM)
—
P/E (Fwd)
7.94
EPS (TTM)
$-0.42
EPS (Fwd)
$0.52
ROE
-238.5%
ROA
-13.4%
Cash
$34.5M
Total Debt
$6.2M
Free CF
-$4.2M
52W Change
-60.5%
Annual Financials
Cash vs Debt
Where LFMD stands vs its 150-day and 200-day moving averages
As of the July 9, 2026 close, LFMD finished 20.26% above its 150-day moving average ($3.90) and 7.82% above its 200-day moving average ($4.35). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LFMD overbought or oversold?
At the July 9, 2026 close, LFMD's RSI(14) was 47.4, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
LifeMD, Inc. holds $34.5M in cash against $6.2M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$4.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -238.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $119.0M (2022) to $194.1M (2025), reflecting a 63% increase over the period.
A beta of 1.99 means LFMD is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, LFMD has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing LFMD.